


## Welcome to Nucleic Acid Isar Valley

On May 1st, the future cluster for nucleic acid therapeutics (Cluster for Nucleic Acid Therapeutics Munich, C-NAT-M) started, and twenty two successful applications made the Nucleic Acid Isar Valley streamed.



C-NAT-M is an innovation network from science and industry, which is funded with **five million euros annually** by the federal government, the Free State of Bavaria and the companies involved.

The two Munich universities Ludwig-Maximilians Universität (LMU) and Technical University Munich (TUM) are working together with the Helmholtz Center for Health Research Munich and the international companies Roche Diagnostics, Sanofi Genzyme and CureVac.

In addition, C-NAT M is supported by highly innovative nucleic acid research biotech companies in the Munich region such as **baseclick GmbH**, Rntatics, Ella Biotech, Metabion, Ethris, XL-Proteins, Dynamic Biosensors, Tubulis and Isar Bioscience.

The multilateral cooperation of the C-NAT-M focuses on the development of nucleic acid-based therapeutics and vaccines. The latest discoveries give hope that the possibility of being able to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many diseased people.

**“Scientists from very different disciplines work together to achieve the goals.”**

baseclick GmbH will lead a research team comprising researchers from LMU university and her own team in order to develop new applications for mRNA therapeutics and vaccines. baseclick’s CEO Dr. Thomas Frischmuth points out: *“There is no substance class that is better suited to personalized medicine than nucleic acids in particular mRNA.”* baseclick and researchers from the LMU will modify mRNA for better stability, translation and cellular targeting.